Funding: Unrestricted research grant support was provided by Proctor & Gamble, Servier, and Solvay and Wyeth.
Postmenopausal hormone therapy: the pros and cons
Article first published online: 25 MAR 2004
Internal Medicine Journal
Volume 34, Issue 3, pages 109–114, March 2004
How to Cite
Rivera-Woll, L. M. and Davis, S. R. (2004), Postmenopausal hormone therapy: the pros and cons. Internal Medicine Journal, 34: 109–114. doi: 10.1111/j.1444-0903.2004.00555.x
Conflicts of interest: Susan Davis is a consultant and on the advisory board for Servier, Cellergy, Acrux and Proctor & Gamble. She is also an investigator for Proctor & Gamble, Servier, Acrux and Organon.
- Issue published online: 25 MAR 2004
- Article first published online: 25 MAR 2004
- Received 13 May 2003;accepted 18 September 2003.
- hormone therapy;
- risk versus benefit.
The use of postmenopausal hormone therapy (HT) has recently generated much debate following the results of various large randomised controlled trials. This has challenged physicians to reassess the use of HT in each individual woman within the realm of her symptomatology and risk profile for long-term illnesses. There are several areas of definite benefit or risk and many areas of uncertainty. The results of recent randomised controlled trials pertain to the specific HT regimens used and the characteristics of the study groups, such that the conclusions cannot be extrapolated to the use of HT in general. (Intern Med J 2004; 34: 109−114)